Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...
8don MSN
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
3don MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback